We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CLS-AX

News List

Clearside Biomedical Completes Dosing in First Cohort Trial of CLS-AX for Wet AMD americanpharmaceuticalreview
March 05, 2021
Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical Begins Enrollment for CLS-AX Trial for Wet AMD americanpharmaceuticalreview
January 20, 2021
Clearside Biomedical announced the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical Announces FDA Acceptance of CLS-AX IND americanpharmaceuticalreview
August 14, 2020
Clearside Biomedical announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CLS-AX (axitinib injectable suspension) ...